Qwixel Therapeutics is an early stage Biotherapeutics company focused in Oncology. Qwixel has developed a unique and proprietary platform technology enabling the targeted delivery of Interferons to tumors while reducing their systemic activation of immune cells. An initial product designed to target multiple myeloma as well as many solid tumors has potent direct anti-tumor activity as well as the potential to stimulate an anti-tumor immune response. Qwixel has a strong IP position with an experienced management team on both the science and business ends.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):